Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms

Haematologica

Volumn 89, Issue 11, 2004, Pages 1322-1331

  Fernàndez, Verònica ^a   Jares, Pedro ^a   Beà, Sílvia ^a   Salaverria, Itziar ^a   Guino, Elisabet ^b   De Sanjosé, Silvia ^b   Colomer, Dolors ^a   Ott, German ^b   Montserrat, Emili ^a   Campo, Elias ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

DR4; DR5; Mantle cell lymphoma; Polymorphisms; TRAIL receptors

Indexed keywords

CYTOKINE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CHROMOSOME 8P; CHRONIC LYMPHATIC LEUKEMIA; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; FOLLICULAR LYMPHOMA; GENE DELETION; GENE FREQUENCY; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; INTRON; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; SEX DIFFERENCE; SILENT GENE;

EID: 9144272267     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 2002;13:199-207.
2. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001;15:1022-32.
3. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000;14:1509-13.
4. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000;103:273-82.
5. Degli-Esposti M. To die or not to die - the quest of the TRAIL receptors. J Leukoc Biol 1999;65:535-42.
6. Kim K, Fisher MJ, Xu SQ, El Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-46.
7. Arai T, Akiyama Y, Okabe S, Saito K, Iwai T, Yuasa Y. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. Cancer Lett 1998;133:197-204.
8. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
10. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20.
11. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-97.
12. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-71.
13. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809-18.
14. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
15. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-0.
16. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92:3018-24.
17. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001;20:399-403.
18. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001; 61: 4942-6.
19. Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM, et al. Mutation analysis and mRNA expression of TRAIL-receptors in human breast cancer. Int J Cancer 2002;102:117-28.
20. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999; 59: 5683-6.
21. Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998;58:3513-8.
22. Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 2001;121:1219-25.
23. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, et al. Nucleotide substitution in the ectodomain of TRAIL-receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001;7:1688-97.
24. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30.
25. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003; 103:221-5.
26. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
27. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70.
28. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-97.
29. Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Benet I, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001; 98:3479-82.
30. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93:4365-74.
31. Bea S, Lopez-Guillermo A, Ribas M, Puig X, Pinyol M, Carrio A, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol 2002;161:957-68.
32. Meetei AR, Rao MR. Generation of multiple site-specific mutations by polymerase chain reaction. Methods Mol Biol 2002;182:95-102.
33. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-6.
34. Ozoren N, El Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-47.
35. McDonald ER III, Chui PC, Martelli PF, Dicker DT, El Deiry WS. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem 2001;276:14939-45.
36. Wu WG, Soria JC, Wang L, Kemp BL, Mao L.TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 2000; 20:4525-9.
37. Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X. Death receptor 4 and bladder cancer risk. Cancer Res 2003; 63:1157-9.
38. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
39. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
40. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997;99:618-24.